Sakamako daga gwajin lokaci2 yana goyan bayan ra'ayin cewa gudanarwar IFN-β don maganin COVID-19 na subcutaneous yana haɓaka saurin murmurewa kuma yana rage mace-mace..
Halin ban mamaki da cutar ta COVID-19 ta gabatar ya ba da garantin bincika hanyoyi daban-daban don magance mummunan lamuran COVID-19. Ana gwada sabbin magunguna da yawa kuma ana sake dawo da magungunan da ake dasu. corticosteroids an riga an gano suna da amfani. An riga an yi amfani da maganin Interferon don cututtukan ƙwayoyin cuta kamar hanta. Za a iya amfani da IFN akan SARS CoV-2 a cikin COVID-19?
A cikin gwaje-gwaje na yau da kullun a baya, IFN ta tabbatar da yin tasiri a kan SARS CoV da MERS ƙwayoyin cuta. A cikin Yuli 2020, an ba da rahoton gudanar da Interferon-β ta hanyar nebulisation (watau inhalation na huhu) don nuna sakamako mai ban sha'awa a cikin kula da matsanancin COVID-19 dangane da bayanai daga gwaji na asibiti na lokaci na 2 1,2.
Yanzu, sabon rahoto dangane da bayanai daga gwaji na asibiti na kashi na 2 da aka gudanar kan marasa lafiya 112 tare da COVID-19 da ke asibiti a Pitié-Salpêtrière a Paris, Faransa ya ba da shawarar cewa gudanar da IFN- β ta hanyar subcutaneous yana haɓaka adadin murmurewa da rage mace-mace a cikin COVID-19. lokuta 3.
Interferon (IFN) sunadaran sunadaran da sel masu gida suka ɓoye don amsawa ga cututtukan hoto don siginar sauran ƙwayoyin cuta don kasancewar ƙwayoyin cuta. An sami karin martanin kumburin kumburi a cikin wasu marasa lafiya na COVID-19 ana danganta su da raunin amsawar IFN-1 da toshewa. IFN-β asiri. Ana amfani da shi a cikin Sin don kula da ciwon huhu saboda SARS CoV duk da haka ba a daidaita amfani da shi ba 4.
Gwajin gwaji na asibiti na kashi 3 don amfani da Interferon (IFN) don kula da masu cutar COVID-19 mai tsanani a halin yanzu yana kan ci gaba. Amincewa zai dogara ne akan ko sakamakon ƙarshe yana cikin kewayon karɓuwa wanda masu gudanarwa suka tsara.
***
Sources:
- NHS 2020. Labarai- Magungunan da aka shaka yana hana marasa lafiya COVID-19 yin muni a gwajin Southampton. An buga akan 20 Yuli 2020. Akwai akan layi a https://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Research/News-and-updates/Articles/Inhaled-drug-prevents-COVID-19-patients-getting-worse-in-Southampton-trial.aspx An shiga ranar 12 ga Fabrairu, 2021.
- Monk PD., Marsden RJ., Tear VJ., et al., 2020. Tsaro da ingancin inhaled interferon beta-1a (SNG001) don lura da SARS-CoV-2 kamuwa da cuta: bazuwar, biyu-makafi, placebo- sarrafawa, gwaji na lokaci 2. Magungunan Numfashi na Lancet, Akwai akan layi 12 Nuwamba 2020. DOI: https://doi.org/10.1016/S2213-2600(20)30511-7
- Dorgham K., Neumann AU., et al 2021. Yin la'akari da keɓaɓɓen maganin Interferon-β don COVID-19. Magungunan rigakafi Chemotherapy. An buga Online 8 Fabrairu 2021. DOI: https://doi.org/10.1128/AAC.00065-21
- Mary A., Hénaut L., Macq PY., et al 2020. Dalilin COVID-19 Jiyya ta Nebulized Interferon-β-1b-Bita na Adabi da Ƙwarewar Farko na Keɓaɓɓu. Ƙididdiga a Ilimin Magunguna., 30 Nuwamba 2020. DOI:https://doi.org/10.3389/fphar.2020.592543.
***